ArticleParasites & vectors2016
Early reduction of Leishmania infantum-specific antibodies and blood parasitemia during treatment in dogs with moderate or severe disease.
Article in Parasites & vectors, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence-Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis.Veterinary dermatology · 2025Guideline
- Evaluation of rKDDR-Plus ELISA in Dogs with Different Clinical and Serological Profiles ofAnimals : an open access journal from MDPI · 2026Article
- Updated Canine Leishmaniosis Working Group recommendations for leishmaniosis in dogs: Q&A on clinical management.Parasites & vectors · 2026Review
- Hair quantitative PCR outperforms blood analysis for detecting Leishmania DNA in dogs: a non-invasive tool for clinical states of infection.Parasites & vectors · 2026Article
- Changes in serological, inflammatory, and serum protein electrophoretic markers during ongoing meglumine antimoniate plus allopurinol therapy in canine leishmaniosis.Veterinary research communications · 2026Article
- A newly developed rapid K39-based LeishmaCHECK Ab ELISA for high-throughput serological screening of canine leishmaniasis.Current research in parasitology & vector-borne diseases · 2026Article
- Importance of Different Parameters for Monitoring Dogs withPathogens (Basel, Switzerland) · 2025Article
- Unveiling prognostic indicators in canine leishmaniosis: two decades of evidence.Parasites & vectors · 2025Article
- Immunomodulation of Patients with Canine Visceral Leishmaniasis at Different Stages: A 12-Month Follow-Up Study Using LaSap.Vaccines · 2025Article
- Impact of levels of parasitemia and antibodies, acute-phase proteins, as well as stays abroad on hematological and biochemical parameters in 342 dogs with acute Babesia canis infection.Parasites & vectors · 2025Article
- Humoral and T-Cell-Mediated Immunity AgainstPathogens (Basel, Switzerland) · 2025Article
- Treatment ofMicroorganisms · 2025Review
- Clinical, Immunological and Pathological Characteristics of Ischemic Dermatopathy in Dogs with Leishmaniosis.Pathogens (Basel, Switzerland) · 2025Article
- Evidence for in vivo resistance against allopurinol in a dog infected with Leishmania infantum by reduction in copy numbers of the S-adenosylmethionine synthetase (METK) gene.Parasites & vectors · 2024Article
- Development of a Simple IFN-γ Release Whole Blood Assay for the Assessment ofAnimals : an open access journal from MDPI · 2024Article
- Critically Appraised Topic on Canine Leishmaniosis: Does Treatment with Antimonials and Allopurinol Have the Same Clinical and Clinicopathological Efficacy as Treatment with Miltefosine and Allopurinol, after One Month of Treatment?Veterinary sciences · 2024Article
- A blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of LeisguardParasites & vectors · 2023Article
- Effect of Local Administration of Meglumine Antimoniate and Polyhexamethylene Biguanide Alone or in Combination with a Toll-like Receptor 4 Agonist for the Treatment of Papular Dermatitis due toPathogens (Basel, Switzerland) · 2023Article
- Signalment, Immunological and Parasitological Status and Clinicopathological Findings ofAnimals : an open access journal from MDPI · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeishmania infantum-specific antibodies are used extensively for the diagnosis and monitoring of treatment in canine leishmaniosis. Different views have been described for the measurement of L. infantum antibody levels for the monitoring of anti-leishmanial treatment. In addition, molecular techniques using blood are frequently employed in the clinical setting. However, there are not enough studies to prove the usefulness of PCR in diagnosis, treatment monitoring and in assessing the prognosis of the disease. The objectives of this study were to evaluate L. infantum-specific antibodies and blood parasitemia at the time of diagnosis and during treatment and to correlate these with the dog's clinical status.
methodsThirty-seven dogs were diagnosed and followed-up during treatment (days 30, 180 and 365). The treatment protocol consisted of a combination of meglumine antimoniate for one month and allopurinol for at least one year. Leishmania infantum-specific antibodies and blood parasitemia were assessed by an end point sera dilution ELISA and by real-time PCR, respectively.
resultsThe majority of dogs were classified as LeishVet stage II (moderate disease) at the time of diagnosis (86 %) and the rest as stage III. Results showed variable levels of specific antibodies at the time of diagnosis [median ± interquartile range (IQR): 1372 ± 8803 ELISA units (EU)]. Twenty-three seropositive dogs (64 %) were detected as PCR-positive at the time of diagnosis. Interestingly, a rapid significant antibody level reduction was observed by day 30 of treatment (median ± IQR: 604 ± 2168 EU). A continuing significant decrease of specific antibodies was also found at days 180 (median ± IQR: 201 ± 676 EU) and 365 (median ± IQR: 133 ± 329 EU) in association with clinical improvement. A significant blood parasitemia reduction was also observed at all time points studied. Mean parasites/ml ± SD were 19.4 ± 79.1 on day 0, 2.2 ± 11.7 on day 30, 0.9 ± 2.9 on day 180, and 0.3 ± 0.7 on day 365.
conclusionsThis study reports a significant reduction of L. infantum antibodies measured by an end point sera dilution ELISA method after 30 days of treatment associated with clinical improvement. A low proportion of sick dogs with moderate disease were negative by blood real-time PCR at the time of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.